Find Clinical Trials

← Back
January 23, 2025 in Lung

PrE1702

Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients
Read More
December 12, 2024 in Lung

SGNB6A-002

A randomized, phase 3, open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)
Read More
October 10, 2024 in Lung

TRITON/D419ML0003

A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung…
Read More
June 17, 2024 in Lung

EA5221

Randomized Phase 3 Clinical Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Read More
September 27, 2023 in Lung

KRYSTAL-17

A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Read More
June 26, 2023 in Lung

S1900G

A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Read More
April 3, 2023 in Lung

S2302

Non-Chemotherapy Treatment (ramucirumab plus pembrolizumab) or Usual Care for Advanced Non-Small Cell Lung Cancer Following Immunotherapy
Read More
September 14, 2022 in Lung

LungMAP

LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Read More
September 14, 2022 in Lung

EA5162

EA5162: Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR
Read More
August 3, 2022 in Lung

A092001

A092001: Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or without Immunotherapy for Peritoneal Mesothelioma
Read More
July 11, 2022 in Lung

S1933

S1933: A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status
Read More
July 11, 2022 in Lung

S1827

S1827: A Randomized Phase III Trial of MRI Surveillance with or without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer
Read More
July 1, 2022 in Lung

LU007

LU007: RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC: RAPTOR trial (NCT # NCT04402788)
Read More
June 30, 2022 in Lung

EA5182

EA5182: Randomized Phase 3 Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Lung Cancer (NCT04181060)
Read More
June 30, 2022 in Lung

E4512

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Read More
June 30, 2022 in Lung

CC009

CC009: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases from Small Cell Lung Cancer
Read More
June 30, 2022 in Lung

A082002

A082002: A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or without SBRT for PD-L1-Negative, Advanced Non-small Cell Lung Cancer (NCT04929041)
Read More
June 30, 2022 in Lung

A081801

A081801 Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO
Read More